KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

A randomized phase III study optimizing adjuvant osimertinib for resected EGFR-mutant stage II-III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01).

Ken Onodera, Yoshinori Okada, Yujin Kudo, Masaya Yotsukura, Keisuke Asakura, Yasushi Goto, Satoshi Shiono, Shinichi Toyooka, Yoshimasa Maniwa, Toyofumi Fengshi Chen-Yoshikawa, Shun-Ichi Watanabe, Masataka Taguri, Nodoka Seya, Tomonori Mizutani, Hideo Kunitoh, Japan Cancer Treatment Optimization group (JACTOP), Norihiko Ikeda

Jpn J Clin Oncol hyag185

PMID42955056
PMCID-
DOI10.1093/jjco/hyag185
发表日期2026-10-29
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II-III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。